Upper GI 2017

First page Table of contents Previous page 152 Next page Last page

USA – CALGB 80803

Key results (cont.)

pCR rates

Induction mFOLFOX (n=129)

Induction carboplatin/paclitaxel (n=128)

PET responder 73/129 (57%)

PET non-responder 39/129 (30%)

PET responder 64/128 (50%)

PET non-responder 49/128 (38%)

Concurrent carboplatin/paclitaxel

Concurrent mFOLFOX

pCR: 7/41* (17.0%)

pCR: 24/64 (37.5%)

pCR: 7/37 (19.0%)

pCR: 7/56 (12.5%)

*One ypTON1 excluded

Goodman KA, et al. J Clin Oncol 2017; 35 (suppl 4): abstr 1